1. Home
  2. AKRO vs GEO Comparison

AKRO vs GEO Comparison

Compare AKRO & GEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • GEO
  • Stock Information
  • Founded
  • AKRO 2017
  • GEO 1984
  • Country
  • AKRO United States
  • GEO United States
  • Employees
  • AKRO N/A
  • GEO N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • GEO Homebuilding
  • Sector
  • AKRO Health Care
  • GEO Consumer Discretionary
  • Exchange
  • AKRO Nasdaq
  • GEO Nasdaq
  • Market Cap
  • AKRO 3.9B
  • GEO 3.9B
  • IPO Year
  • AKRO 2019
  • GEO 1994
  • Fundamental
  • Price
  • AKRO $54.20
  • GEO $23.62
  • Analyst Decision
  • AKRO Strong Buy
  • GEO Strong Buy
  • Analyst Count
  • AKRO 6
  • GEO 5
  • Target Price
  • AKRO $82.50
  • GEO $47.33
  • AVG Volume (30 Days)
  • AKRO 1.8M
  • GEO 2.5M
  • Earning Date
  • AKRO 08-08-2025
  • GEO 08-06-2025
  • Dividend Yield
  • AKRO N/A
  • GEO N/A
  • EPS Growth
  • AKRO N/A
  • GEO N/A
  • EPS
  • AKRO N/A
  • GEO 0.23
  • Revenue
  • AKRO N/A
  • GEO $2,422,677,000.00
  • Revenue This Year
  • AKRO N/A
  • GEO $8.72
  • Revenue Next Year
  • AKRO N/A
  • GEO $27.89
  • P/E Ratio
  • AKRO N/A
  • GEO $103.55
  • Revenue Growth
  • AKRO N/A
  • GEO 0.50
  • 52 Week Low
  • AKRO $21.02
  • GEO $11.75
  • 52 Week High
  • AKRO $58.40
  • GEO $36.46
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 62.96
  • GEO 35.02
  • Support Level
  • AKRO $53.61
  • GEO $23.75
  • Resistance Level
  • AKRO $56.49
  • GEO $27.20
  • Average True Range (ATR)
  • AKRO 2.40
  • GEO 0.95
  • MACD
  • AKRO -0.08
  • GEO -0.22
  • Stochastic Oscillator
  • AKRO 65.93
  • GEO 12.29

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About GEO Geo Group Inc (The) REIT

The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.

Share on Social Networks: